CA3087968A1 - Anti-siglec-7 antibodies having reduced effector function - Google Patents
Anti-siglec-7 antibodies having reduced effector function Download PDFInfo
- Publication number
- CA3087968A1 CA3087968A1 CA3087968A CA3087968A CA3087968A1 CA 3087968 A1 CA3087968 A1 CA 3087968A1 CA 3087968 A CA3087968 A CA 3087968A CA 3087968 A CA3087968 A CA 3087968A CA 3087968 A1 CA3087968 A1 CA 3087968A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- siglec
- region
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616317P | 2018-01-11 | 2018-01-11 | |
| US62/616,317 | 2018-01-11 | ||
| PCT/US2019/013316 WO2019140273A1 (en) | 2018-01-11 | 2019-01-11 | Anti-siglec-7 antibodies having reduced effector function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3087968A1 true CA3087968A1 (en) | 2019-07-18 |
Family
ID=67219179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3087968A Pending CA3087968A1 (en) | 2018-01-11 | 2019-01-11 | Anti-siglec-7 antibodies having reduced effector function |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11912766B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3737410A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7342005B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019208025A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3087968A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019140273A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960235A (zh) | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| CN119841953A (zh) | 2018-06-08 | 2025-04-18 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| KR20250035502A (ko) * | 2022-03-31 | 2025-03-12 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Siglec-7을 표적으로 하는 이중특이적 자연 살해 인게이저 |
| KR20240168432A (ko) * | 2022-03-31 | 2024-11-29 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 인간 Siglec-7에 대한 항체 및 이의 면역요법을 위한 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120815A2 (en) | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| AU2008272330A1 (en) | 2007-07-04 | 2009-01-08 | Forerunner Pharma Research Co., Ltd. | Anti-Muc17 antibody |
| CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| ES3066738T3 (en) * | 2012-12-21 | 2026-05-14 | Aveo Pharmaceuticals Inc | Anti-gdf15 antibodies |
| ES2861313T3 (es) * | 2014-08-07 | 2021-10-06 | Daiichi Sankyo Co Ltd | Anticuerpo anti Orai1 |
| JP2017532025A (ja) | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 交差反応性siglec抗体 |
| CN115960235A (zh) | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| MX2018006072A (es) * | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| AU2017207807A1 (en) | 2016-01-12 | 2018-07-12 | Palleon Pharmaceuticals Inc. | Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer |
| CN108699158B (zh) * | 2016-03-08 | 2022-06-03 | 依奈特制药公司 | Siglec中和抗体 |
| IL264674B2 (en) * | 2016-08-05 | 2023-09-01 | Allakos Inc | Antibodies to siglec7 for cancer treatment |
-
2019
- 2019-01-11 WO PCT/US2019/013316 patent/WO2019140273A1/en not_active Ceased
- 2019-01-11 AU AU2019208025A patent/AU2019208025A1/en not_active Abandoned
- 2019-01-11 CA CA3087968A patent/CA3087968A1/en active Pending
- 2019-01-11 JP JP2020538029A patent/JP7342005B2/ja active Active
- 2019-01-11 US US16/961,197 patent/US11912766B2/en active Active
- 2019-01-11 EP EP19739010.7A patent/EP3737410A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511298A (ja) | 2021-05-06 |
| JP7342005B2 (ja) | 2023-09-11 |
| EP3737410A4 (en) | 2022-04-20 |
| AU2019208025A1 (en) | 2020-09-03 |
| US20210054072A1 (en) | 2021-02-25 |
| WO2019140273A1 (en) | 2019-07-18 |
| US11912766B2 (en) | 2024-02-27 |
| EP3737410A1 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773162B2 (en) | Anti-Siglec-7 antibodies for the treatment of cancer | |
| RU2733315C2 (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
| TWI793325B (zh) | 對cd3具特異性之抗體及其用途 | |
| US11912766B2 (en) | Anti-Siglec-7 antibodies having reduced effector function | |
| CA3100829A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| IL293926A (en) | Antibodies specific for cd47, pd-l1, and uses thereof | |
| CA3174908A1 (en) | Fusion proteins and uses thereof | |
| JP2017507953A (ja) | 抗cd38抗体との併用療法 | |
| CA2940865A1 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| WO2021139682A1 (en) | Anti-galectin-9 antibody and uses thereof | |
| US20250051464A1 (en) | Epha2 antibodies | |
| US20250042996A1 (en) | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 | |
| WO2019232323A1 (en) | Bi-specific antibodies and use thereof | |
| CA3100828C (en) | Antibodies specific for cd3 and uses thereof | |
| TW202523694A (zh) | 抗muc16抗體及其用途 | |
| HK40033769A (en) | Cd70 combination therapy | |
| HK40046552B (en) | Antibodies specific for cd3 and uses thereof |